Key result
Elective implantation of the Carbostent in patients at high risk of restenosis resulted in a 6-month event-free survival rate of 74% and a binary restenosis rate of 25%.
Why the study?
Does Carbostent implantation provide favorable clinical and angiographic outcomes in patients at high risk of restenosis and target vessel failure?
Cohort (n=112)
Does Carbostent implantation provide favorable clinical and angiographic outcomes in patients at high risk of restenosis and target vessel failure?
Carbostent implantation appears safe and effective, yielding acceptable angiographic and clinical outcomes in a high-risk patient population.
No takes yet. Share an insight, caveat, or question.
May support Carbostent in high-risk restenosis; leaves open randomized confirmation of benefit.
Antoniucci et al. (2001) conducted a cohort in High risk of restenosis and target vessel failure (n=112). Carbostent implantation was evaluated on 6-month event-free survival rate. Elective implantation of the Carbostent in patients at high risk of restenosis resulted in a 6-month event-free survival rate of 74% and a binary restenosis rate of 25%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: